Ventyx CFO Martin D. Auster departs; Roy Gonzales appointed interim CFO/PAO

Ventyx Biosciences, Inc.

Appointed Roy M. Gonzales as interim principal financial officer and interim principal accounting officer effective Aug 30, 2024, replacing Martin D. Auster.
Dr. Auster's separation agreement provides nine months base salary continuation, COBRA reimbursement, and accelerated vesting of equity vesting within three months.
Gonzales joined as SVP of Finance in April 2024; previously VP of Accounting; salary $350k, 30% target bonus.
No changes to Gonzales' compensation or terms from his interim appointment.
No family relationships or material transactions with Gonzales requiring disclosure.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Roy M. Gonzales

interim principal financial officer and interim principal accounting officer

Ventyx Biosciences, Inc.

Effective: 2024-08-30
Filed: August 30, 2024, 7:59 PM ET

appointed Roy M. Gonzales, the Company’s Senior Vice President of Finance, as the Company’s interim principal financial officer and interim principal accounting officer, effective as of August 30, 2024

Departed

Martin D. Auster

Chief Financial Officer

Ventyx Biosciences, Inc.

Effective: 2024-08-30
Successor: Roy M. Gonzales
Filed: August 30, 2024, 7:59 PM ET

Dr. Auster ceased employment as the Company’s Chief Financial Officer, effective as of August 30, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Roy M. Gonzales was appointed as interim principal financial officer and interim principal accounting officer at Ventyx Biosciences, Inc..

Action: appointed
Role: interim principal financial officer and interim principal accounting officer

Exact text from the filing

appointed Roy M. Gonzales, the Company’s Senior Vice President of Finance, as the Company’s interim principal financial officer and interim principal accounting officer, effective as of August 30, 2024

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Martin D. Auster resigned as Chief Financial Officer at Ventyx Biosciences, Inc..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

Dr. Auster ceased employment as the Company’s Chief Financial Officer, effective as of August 30, 2024.

View on SEC.gov

Source: SEC EDGAR

accession 0001193125-24-210399

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.